Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 50/100

Affimed NV & Artiva Biotherapeutics Announce Partnership Transcript

Nov 03, 2022 / 02:30PM GMT
Release Date Price: $20.25 (+19.82%)
Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to today's conference call by Affimed NV and Artiva Biotherapeutics. (Operator Instructions) Please note this conference call is being recorded.

I now would like to hand the call over to your host for today, Alex Fudukidis, Director, Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, Howard, and thank you all for joining us today to review today's exciting developments, the partnership with Artiva Biotherapeutics and a brief overview of the updated data from the combination study of AFM13 with cord blood-derived natural killer cells. We issued the 2 relevant press releases earlier today, both of which can be found on the Investor Relations section of our website. Please note that the associated presentation is also on the website.

On the call today, we have management -- the management team from Artiva and Affimed. From Artiva, we have Dr. Fred Aslan, President and Chief Executive Officer; and Dr. Peter Flynn, Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot